Department of Emergency Medicine, University of British Columbia, Vancouver, BC, Canada.
Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
CJEM. 2024 May;26(5):349-358. doi: 10.1007/s43678-024-00691-7. Epub 2024 May 5.
We utilized quality improvement (QI) approaches to increase emergency department (ED) provider engagement with research participant enrollment during the opioid crisis and coronavirus disease (COVID-19) pandemic. The context of this work is the Evaluating Microdosing in the Emergency Department (EMED) study, a randomized trial offering buprenorphine/naloxone to ED patients through randomization to standard or microdosing induction. Engaging providers is crucial for participant recruitment to our study. Anticipating challenges sustaining long-term engagement after a 63% decline in provider referrals four months into enrollments, we applied Plan-Do-Study-Act (PDSA) cycles to develop and implement an engagement strategy to increase and sustain provider engagement by 50% from baseline within 9 months.
Our engagement strategy was centered on Coffee Carts rounds: 5-min study-related educational presentations for providers on shift; and a secondary initiative, a Suboxone Champions program, to engage interested providers as study-related peer educators. We used provider referrals to our team as a proxy for study engagement and report the percent change in mean weekly referrals across two PDSA cycles relative to our established referral baseline.
A QI approach afforded real-time review of interventions based on research and provider priorities, increasing engagement via mean weekly provider referrals by 14.5% and 49% across two PDSA cycles relative to baseline, respectively.
Our Coffee Carts and Suboxone Champions program are efficient, low-barrier, educational initiatives to convey study-related information to providers. This work supported our efforts to maximally engage providers, minimize burden, and provide life-saving buprenorphine/naloxone to patients at risk of fatal overdose.
我们利用质量改进(QI)方法来增加急诊(ED)提供者在阿片类药物危机和冠状病毒病(COVID-19)大流行期间参与研究参与者招募的积极性。这项工作的背景是评估急诊微剂量(EMED)研究,这是一项随机试验,通过对标准或微剂量诱导进行随机分组,向 ED 患者提供丁丙诺啡/纳洛酮。招募提供者对于我们的研究至关重要。预计在招募四个月后,由于提供者推荐减少了 63%,长期参与将面临挑战,因此我们应用计划-执行-研究-行动(PDSA)循环来制定和实施一项参与策略,在 9 个月内将提供者的参与度提高并维持在基线水平的 50%。
我们的参与策略以咖啡车轮询为中心:在轮班时为提供者提供 5 分钟的与研究相关的教育演示;以及一个二级计划,即丁丙诺啡冠军计划,以吸引有兴趣的提供者作为与研究相关的同行教育者。我们使用提供者向我们团队的推荐作为研究参与的代理,并报告在两个 PDSA 循环中相对于我们既定的推荐基线的每周平均推荐变化百分比。
QI 方法根据研究和提供者的重点实时审查干预措施,通过每周平均提供者推荐分别提高了 14.5%和 49%,相对于基线。
我们的咖啡车和丁丙诺啡冠军计划是向提供者传达研究相关信息的高效、低门槛、教育举措。这项工作支持了我们最大限度地参与提供者、最小化负担以及为有致命过量风险的患者提供救命的丁丙诺啡/纳洛酮的努力。